Zai Lab Q3 revenue $57.5M (+33% YoY); net loss widens to $161.2M on Seagen payment

Zai Lab Ltd

2022-Q3 EPS reported -$0.40 revenue$152,439,000

Total revenues $57.5M vs $43.1M YoY; net product revenue led by ZEJULA $39.2M.
Net loss $161.2M vs $96.4M YoY, reflecting $30M upfront to Seagen and $36.7M FX loss.
Cash & equivalents $1.12B; company expects runway through 2025.
Entered collaboration with Seagen for TIVDAK in Greater China.
Appointed Dr. Peter Huang as CSO and Alette Verbeek as SVP Global Strategic Partnering.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Zai Lab Ltd reported the three months ended September 30, 2022 results: revenue $57.5 million.

Period: the three months ended September 30, 2022
Revenue: $57.5 million
Result: reported results

Exact text from the filing

expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Zai Lab Announces Third Quarter 2022 Financial Results and Corporate Updates – Revenue of $57.5 million for the third quarter of 2022, representing a 33% increase y-o-y and a 19% increase q-o-q; continued revenue growth led by ZEJULA – Regional strategic collaboration for TIVDAK ®

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Zai Lab Ltd filing history →

Source: SEC EDGAR

accession 0001628280-22-029232

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.